RxDoctor Payments DataLook up a doctor →

Lauren Hayward, MD

Rheumatology · Oxford, MSNPI 1619356722

Payments from drug & device makers

$17,228in general payments, 2019–2025

Across 967 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Amgen$4K
  • Johnson & Johnson$2K
  • Novartis$1K
  • Boehringer Ingelheim$1K
  • UCB, Inc.$854
  • plus $4K from 21 others

What the payments were for

  • Food & beverage$16,86998%
  • Education$3592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,228 in reported general payments places this provider in the 70th percentile of 44 rheumatology providers in Mississippi.

See all rheumatology providers in Mississippi

Medicare billing

Part B allowed, 2024
$82,951
Medicare patients
312
Services billed
1,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept67$473,332
Humira(Cf) PenAdalimumab26$171,264
Cosentyx Unoready PenSecukinumab23$162,790
RinvoqUpadacitinib25$153,062
Cimzia (2 Pack)Certolizumab Pegol21$131,316
KevzaraSarilumab11$45,427
Hydroxychloroquine Sulfate312$10,079
RasuvoMethotrexate/Pf13$8,262
MethotrexateMethotrexate Sodium244$6,553
Mycophenolic AcidMycophenolate Sodium13$3,481
Leflunomide92$3,283
Mycophenolate Mofetil23$1,848
Prednisone199$1,125
Allopurinol80$477
Alendronate Sodium81$353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$4,328$153,06225 claims
UCB, Inc.Cimzia (2 Pack)$854$131,31621 claims
SanofiKevzara$146$45,42711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 44 rheumatology providers in Mississippi.

Other rheumatology in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →